Background
Trastuzumab is a humanized monoclonal antibody used in the treatment of HER2-positive breast cancer. Trastuzumab binds close to the transmembrane domain, inhibiting HER2 dimerization. It induces antibody-dependent cell-mediated cytotoxicity.
Product Details
| Reactivity | Human |
| Specificity | Detects human ErbB2/Her2 in direct ELISA. This non-therapeutic antibody uses the same variable region sequences (VH, VL) as the therapeutic antibody Trastuzumab. This product is for research use only. |
| Source | Recombinant Monoclonal Human IgG1 Clone #FB001 |
| Purification | Protein A/G purified from CHO cell culture supernatant |
| Immunogen | Human ErbB2/Her2 |
| Endotoxin Level | <0.10 EU per 1 µg of the antibody by the LAL method |
| Formulation | 0.2 µm filtered solution in PBS |
| Applications | • Flow Cytometry: 0.25 µg/106 cells. • Inhibition of Cell Growth: Measured by its ability to inhibit proliferation in the SK-BR-3 human breast cancer cell line. The ED50 for this effect is typically 15-75 ng/ml. |
| Reconstitution | Reconstitute at 0.5 mg/ml in sterile 1xPBS |
| Shipping | The product is shipped with polar packs. Upon receipt, store it immediately at -20 to -70°C |
| Storage Conditions | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. • 12 months from the date of receipt at -20 to -70°C as supplied. • 1 month at 2 to 8°C under sterile conditions |